Negative / Null Result ReportMedicine
Falkenhorst J, Ivanyi P, Schulz T et al. · 2025 · Clinical cancer research : an official journal of the American Association for Cancer Research
Purpose Imatinib resistance is conferred by secondary mutations within the ATP-binding pocket or the activation loop of KIT in gastrointestinal stromal tumors (GIST). Ponatinib is active against KIT secondary activation loop and the…
View details →DOI: 10.1158/1078-0432.ccr-25-0222 Negative / Null Result ReportOpen accessMedicine
Sahebjam S, Bazer DA, Rhun EL et al. · 2026 · Neuro-oncology advances
Background Abemaciclib is a selective cyclin-dependent kinase 4 and 6 inhibitor that penetrates the blood-brain barrier, resulting in comparable concentrations in tissue and plasma. The primary objective of this nonrandomized Simon…
View details →DOI: 10.1093/noajnl/vdag005 Negative / Null Result ReportOpen accessMedicine
Kim DW, Kim RD, Jimenez MM et al. · 2025 · The oncologist
Background Ramucirumab plus paclitaxel after progression on fluoropyrimidine/platinum in metastatic gastric (GA) and gastroesophageal junction adenocarcinoma (GEJC) has shown improvement in overall survival over paclitaxel alone. However,…
View details →DOI: 10.1093/oncolo/oyaf303 Negative / Null Result ReportOpen accessMedicine
Leelahawong P, Ketsuwan C · 2026 · Journal of clinical medicine
Background/Objectives : To evaluate whether adjunctive silodosin improves the stone-free rate (SFR) and clinical outcomes of extracorporeal shock wave lithotripsy (ESWL) for renal calculi. Methods : In this prospective randomised…
View details →DOI: 10.3390/jcm15072471 Negative / Null Result ReportOpen accessMedicine
Chibaudel B, Dourthe LM, André T et al. · 2026 · Signal transduction and targeted therapy
Managing unresectable metastatic colorectal cancer (mCRC) requires a comprehensive strategy. While chemotherapy, anti-angiogenic, and anti-epidermal growth factor receptor (EGFR) agents are available, strategy trials are needed to optimize…
View details →DOI: 10.1038/s41392-026-02639-y Negative / Null Result ReportOpen accessMedicine
Wheless MC, Stockton S, Soares HP et al. · 2025 · The oncologist
Background Mutations in TP53 are common in gastroesophageal cancer and portend a poor prognosis. Tumor cells with TP53 mutations increasingly rely on ataxia-telangiectasia and Rad3-related (ATR) protein to respond to and repair DNA damage…
View details →DOI: 10.1093/oncolo/oyaf400 Negative / Null Result ReportOpen accessMedicine
Nagatani Y, Kiyota N, Yamazaki T et al. · 2026 · Japanese journal of clinical oncology
Background Salivary gland cancer (SGC) is rare and has various histological types. This rarity and heterogeneity have hindered elucidation of the therapeutic contribution of systemic therapy, including immune checkpoint inhibitors, to…
View details →DOI: 10.1093/jjco/hyaf192 Negative / Null Result ReportMedicine
Shiraishi Y, Shimose T, Tobino K et al. · 2025 · Lung cancer (Amsterdam, Netherlands)
Background The current standard of care for advanced non-small cell lung cancer (NSCLC) without driver oncogenes is platinum-based chemotherapy together with immune checkpoint inhibition. However, most phase 3 trials of such combination…
View details →DOI: 10.1016/j.lungcan.2025.108543 Negative / Null Result ReportOpen accessMedicine
Lan H, Lu M, Li S et al. · 2026 · Frontiers in medicine
Objective High-quality bowel preparation is essential for accurate colonoscopy. Currently, linaclotide is used as an adjunctive agent supporting bowel preparation, but evidence for its combination with oral sulfate solution (OSS) remains…
View details →DOI: 10.3389/fmed.2026.1696298 Negative / Null Result ReportMedicine
Damas OM, Leo M, Colina N et al. · 2025 · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Background & aims Diet may influence ulcerative colitis (UC), but its impact on medication response remains unclear. We examined whether two 5-day cycles of a low-calorie, plant-based (LC-PB), fasting-mimicking diet could improve UC…
View details →DOI: 10.1016/j.cgh.2025.03.020 Negative / Null Result ReportOpen accessMedicine
Masuishi T, Taniguchi H, Kotani D et al. · 2025 · ESMO open
Background Based on the reported antitumor effects of microtubule inhibitors in xenograft models of BRAF V600E mutant colorectal cancer, this multicenter phase II study aimed to evaluate the efficacy and safety of eribulin in patients with…
View details →DOI: 10.1016/j.esmoop.2025.105839 Negative / Null Result ReportOpen accessMedicine
Crown J, Eustace AJ, Collins DM et al. · 2025 · Acta oncologica (Stockholm, Sweden)
Background The docetaxel (T), carboplatin (C) and trastuzumab (H) regimen has been used in the (neo-) adjuvant treatment of HER2+ early stage breast cancer (ESBC). Lapatinib (L) a small molecule HER2 antagonist produces clinical responses…
View details →DOI: 10.2340/1651-226x.2025.43143 Negative / Null Result ReportMedicine
Zhang X, Yan J, Lei Q et al. · 2025 · International journal of radiation oncology, biology, physics
Purpose To investigate the efficacy of metastasis-directed therapy (MDT) when added to camrelizumab (Cam) in patients with recurrent or metastatic nasopharyngeal carcinoma (R/M-NPC). Methods and materials We conducted a randomized,…
View details →DOI: 10.1016/j.ijrobp.2024.10.019 Negative / Null Result ReportMedicine
Rhee H, Henderson LM, Bauer RN et al. · 2024 · Allergy
Background Tryptase, a mast cell protease, has been identified as a potential therapeutic target in managing patients with refractory asthma. We assessed the efficacy, safety, pharmacokinetics, and pharmacodynamics of MTPS9579A, an…
View details →DOI: 10.1111/all.16309 Negative / Null Result ReportMedicine
Yoshioka H, Ishida T, Atagi S et al. · 2025 · Clinical lung cancer
Background We conducted a randomize phase II study to evaluate the efficacy and safety of topoisomerase II inhibitor amrubicin plus topoisomerase I inhibitor irinotecan (AI) compared with cisplatin plus irinotecan (PI) as first-line…
View details →DOI: 10.1016/j.cllc.2024.09.004 Negative / Null Result ReportMedicine
Pressiani T, Balsano R, Giordano L et al. · 2024 · European journal of cancer (Oxford, England : 1990)
Introduction The prognosis of patients with advanced biliary tract cancer (BTC) is still poor, and new strategies improving patients' outcome are needed. In our trial we investigated safety and activity of nab-paclitaxel in combination…
View details →DOI: 10.1016/j.ejca.2024.114196 Replication FailureOpen accessMedicine
Miller RM, Nworu C, McKee L et al. · 2020 · Applied immunohistochemistry & molecular morphology : AIMM
Ataxia-telangiectasia mutated (ATM), a key activator of DNA damage response mechanisms, represents a potential biomarker for targeted gastric carcinoma therapies. A phase II study (Study 39; NCT01063517) designed to investigate the…
View details →DOI: 10.1097/pai.0000000000000786 Negative / Null Result ReportMedicine
Koch MW, Sage K, Kaur S et al. · 2021 · Neurology
Objective To assess whether treatment with the generic drug domperidone can reduce the progression of disability in secondary progressive multiple sclerosis (SPMS), we conducted a phase 2 futility trial following the Simon 2-stage design.…
View details →DOI: 10.1212/wnl.0000000000011863 Negative / Null Result ReportOpen accessMedicine
Wilky BA, Julian KA, Maleddu A et al. · 2025 · Clinical cancer research : an official journal of the American Association for Cancer Research
Purpose Doxorubicin is standard chemotherapy for metastatic soft tissue sarcomas (STS) but also enhances innate/adaptive immune responses by inducing immunogenic cell death. Most STS are immune "cold" tumors that do not respond to immune…
View details →DOI: 10.1158/1078-0432.ccr-25-0618 Negative / Null Result Report
Xu J, Keenan TE, Overmoyer B et al. · 2021 · Preprint
Abstract Purpose: We evaluated the efficacy and safety of poly-(adenosine diphosphate-ribose) polymerase (PARP) 1 and 2 inhibitor veliparib and temozolomide in metastatic breast cancer patients with and without germline BRCA1/2 mutations.…
View details →DOI: 10.21203/rs.3.rs-268461/v1 Negative / Null Result ReportMedicine
Xu J, Keenan TE, Overmoyer B et al. · 2021 · Breast cancer research and treatment
Purpose We evaluated the efficacy and safety of poly-(adenosine diphosphate-ribose) polymerase (PARP) 1 and 2 inhibitor veliparib and temozolomide in metastatic breast cancer patients with and without germline BRCA1/2 mutations. Methods In…
View details →DOI: 10.1007/s10549-021-06292-7 Negative / Null Result ReportMedicine
Comi G, Dadon Y, Sasson N et al. · 2022 · Multiple sclerosis (Houndmills, Basingstoke, England)
Background Interventions targeting the adaptive immune response are needed in multiple sclerosis (MS). Objective Evaluate laquinimod's efficacy, safety, and tolerability in patients with relapsing-remitting multiple sclerosis (RRMS).…
View details →DOI: 10.1177/13524585211032803 Negative / Null Result ReportOpen accessMedicine
Manzo A, Sforza V, Carillio G et al. · 2022 · Frontiers in oncology
Few treatment options are available for patients with small cell lung cancer (SCLC) in progression after a first-line therapy. A novel therapeutic approach is represented by lurbinectedin, a synthetic derivative of trabectedin that works…
View details →DOI: 10.3389/fonc.2022.932105 Negative / Null Result ReportOpen accessMedicine
Schiphorst AT, Arquizan C, Turc G et al. · 2026 · Journal of stroke
Background and purpose Whether perfusion-diffusion mismatch modifies treatment effect of mechanical thrombectomy (MT) for large strokes is poorly known. To address this question, we conducted a post hoc secondary analysis of the Large…
View details →DOI: 10.5853/jos.2025.01200 Negative / Null Result ReportMedicine
Marder G, Quach T, Chadha P et al. · 2024 · Rheumatology (Oxford, England)
Objective To evaluate belimumab addition to the standard of care in patents with refractory idiopathic inflammatory myopathy (IIM). Methods We conducted a 40-week multicentre, randomized, double-blind, placebo-controlled trial with 1:1 IV…
View details →DOI: 10.1093/rheumatology/kead281 Negative / Null Result ReportOpen accessMedicine
White RA, Mezzano-Robinson V, Shi Q et al. · 2025 · The oncologist
Background The parasympathetic branch of the autonomic nervous system has shown tumor-suppressive effects in preclinical models of pancreatic adenocarcinoma (PDAC) by inhibiting cancer stem cells and suppressing inflammatory cytokine…
View details →DOI: 10.1093/oncolo/oyaf162 Negative / Null Result ReportOpen accessMedicine
Zhang CD, Zhou JS, He LY et al. · 2025 · Frontiers in cardiovascular medicine
Objective The aim of this study was to investigate the quantitative flow ratio (QFR) outcomes in the left circumflex artery (LCX) following the placement of a crossover stent from the left main coronary artery (LM) to the left anterior…
View details →DOI: 10.3389/fcvm.2025.1578159 Negative / Null Result ReportMedicine
Raychaudhuri R, Cheng HH, Gulati R et al. · 2026 · European urology oncology
Background and objective Our aim was to determine whether induction chemotherapy followed by PARP inhibitor (PARPi) maintenance improves outcomes for patients with metastatic castration-resistant prostate cancer (mCRPC) harboring…
View details →DOI: 10.1016/j.euo.2025.04.026 Negative / Null Result ReportOpen accessMedicine
Choi SW, Jung HA, Cho HJ et al. · 2023 · Cancer medicine
Background We evaluated the therapeutic efficacy of GC1118, a novel anti-epidermal growth factor receptor (EGFR) monoclonal antibody, in recurrent glioblastoma (GBM) patients with EGFR amplification. Methods This study was a multicenter,…
View details →DOI: 10.1002/cam4.6213 Negative / Null Result ReportMedicine
Voglová B, Hladíková Z, Nemétová L et al. · 2020 · American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
Early worsening of diabetic retinopathy due to sudden glucose normalization is a feared complication of pancreas transplantation; however, its rate or severity has not been studied prospectively. We followed up 43 pancreas and kidney…
View details →DOI: 10.1111/ajt.15924 